This article was originally published in SRA
US Congress approves Peru free trade agreement
You may also be interested in...
With $1.3bn invested in over 200 high-tech start-ups, OurCrowd is now sharpening its focus on medtech. Medtech Insight spoke to founder Jon Medved to find out more.
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.